PMS Registry
In order to understand if there is other unknown side effect during the clinical trail, the PMS (Post-Marketing Study) will be conducted to learn more treatment experiences on patients, and collect their information for further study.
No. 9 of IRPMA COP Benchmarks regulates that all PMS shall go through JIRB, IRB or Ethics Committee and must be registered on the website of IRPMA PMS registry system. It is to ensure the studies conducted on patients have been approved by JIRB, IRB and protect patient’s right of privacy. The public can also get the information and objective of the PMS through the registry system.
Company Name
Title of Study
Update Date
Takeda Taiwan Safety and Effectiveness of Vedolizumab IV in Real World Clinical Practice in Taiwan: A Registry-Based Study 2017-10-12
Bayer XAMINA / Xarelto® on prevention of stroke and non-central nervous system systeMIc embolism in treatment Naïve Asian patients with non-valvular atrial fibrillation. 2017-10-02
Astellas Pharma Taiwan, Inc. A Phase IV Interventional Safety, Efficacy and Quality of Life Study of ELIGARD® in Prostate Cancer Patients in Asia (ELIGANT) 2017-08-23
AbbVie Biopharmaceuticals GmbH Taiwan Branch AbbVie Biopharmaceuticals GmbH Taiwan Branch AbbVie Biopharmaceuticals GmbH Taiwan Branch AbbVie Biopharmaceuticals GmbH Taiwan BranchAbbVie Biopharmaceuticals GmbH Taiwan Branch AbbVie Biopharmaceuticals GmbH Taiwan BranchAbbVie Biopharmaceuticals GmbH Taiwan BranchAbbVie Biopharmaceuticals GmbH Taiwan Branch AbbVie Biopharmaceuticals GmbH Taiwan BranchAbbVie Biopharmaceuticals GmbH Taiwan BranchAbbVie Biopharmaceuticals GmbH Taiwan Branch AbbVie Biopharmaceuticals GmbH Taiwan Branch AbbVie Biopharmaceuticals GmbH Taiwan BranchAbbVie Biopharmaceuticals GmbH Taiwan BranchAbbVie Biopharmaceuticals GmbH Taiwan Branch AbbVie Biopharmaceuticals GmbH Taiwan Branch AbbVie Biopharmaceuticals GmbH Taiwan BranchAbbVie Biopharmaceuticals GmbH Taiwan BranchAbbVie Biopharmaceuticals GmbH Taiwan BranchAbbVie Biopharmaceuticals GmbH Taiwan Branch AbbVie Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in Taiwan 2017-07-07
Astellas Pharma Taiwan, Inc. Non-interventional Study on the Safety and Efficacy of Micafungin for Prevention and Treatment of Fungal Infections in Pediatric Patients in Asia/Oceania – ERADICATE Study 2017-06-07
Daiichi Sankyo Taiwan Non-interventional study on edoxaban treatment in routine clinical practice for patients with non valvular atrial fibrillation in Korea and Taiwan 2017-05-23
Daiichi Sankyo Taiwan Non-Interventional Study on Edoxaban Treatment in Routine Clinical Practice in Patients with Venous Thromboembolism in Korea and Taiwan 2017-05-23
Pfizer Inc. Health-related quality life and health utility among Taiwanese women with advanced/metastatic breast cancer 2017-04-18
Novartis (Taiwan) Co., Ltd Registry of Ruxolitinib Treatment in Patients with Intermediate-2 or High Risk of Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), or Post-essential Thrombocythemia Myelofibrosis (PET-MF) 2017-03-14
Novartis (Taiwan) Co., Ltd A non-interventional, prospective 12-months study to characterize the REAL-life effectiveness and treatment pattern of Secukinumab and current standard of care in patient with chronic plaque psoriasis eligible for systemic treatment in the Asia-Pacific and Middle East regions (REALIA) 2017-02-07
   1 2 3 4